Matches in SemOpenAlex for { <https://semopenalex.org/work/W2036694029> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2036694029 abstract "Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FLHER2 is amplified and/or overexpressed in 15% and 20% of breast and oesophagogastric (OG) cancers, respectively. Results from the recently published ToGA trial reveal that trastuzumab plus standard chemotherapy improves survival in patients with advanced HER2-positive OG cancer compared with chemotherapy alone, which mirrors the survival benefit shown with trastuzumab plus chemotherapy in metastatic breast cancer. The clinical value of lapatinib, already confirmed in advanced trastuzumab-resistant breast cancer, is currently being evaluated in prospective phase III trials for HER2-positive OG cancer in the metastatic setting. Despite improvements in outcome with anti-HER2 therapy, less than half of patients respond to treatment, and predictive biomarkers to lapatinib for breast and OG cancer have not yet been identified.We sought to identify predictive biomarkers of resistance to lapatinib treatment, common to both breast and OG cancer, by using a siRNA screen of genes identified in a primary siRNA screen to sensitise lapatinib-resistant breast cancer cell lines to lapatinib. These genes are found recurrently amplified and overexpressed in 45 HER2-amplified primary breast cancers and 13 HER2-amplified breast cancer cell lines. OG junction cell lines were treated with lapatinib and screened using the siRNA library. We found that silencing of TP53INP1, a gene target of TP53 which is known to be a reactive oxygen species scavenger, resulted in significant sensitisation to lapatinib in two of the most lapatinib-resistant HER2-positive cell lines derived from the OG junction. TP53INP1 was over-expressed, but not amplified, in the sensitised OG junction cell lines.Our results suggest that genes which mediate resistance to anti-HER2 therapy in breast cancer may be relevant to OG cancer. We are currently developing assays for TP53INP1 in tumours for validation within the context of prospective randomised controlled clinical trials for OG cancer.Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3039. doi:10.1158/1538-7445.AM2011-3039" @default.
- W2036694029 created "2016-06-24" @default.
- W2036694029 creator A5015623213 @default.
- W2036694029 creator A5024558533 @default.
- W2036694029 creator A5044049673 @default.
- W2036694029 creator A5057324933 @default.
- W2036694029 creator A5058973407 @default.
- W2036694029 creator A5068311092 @default.
- W2036694029 creator A5069662009 @default.
- W2036694029 creator A5072699629 @default.
- W2036694029 creator A5077235697 @default.
- W2036694029 creator A5087812629 @default.
- W2036694029 date "2011-04-15" @default.
- W2036694029 modified "2023-09-25" @default.
- W2036694029 title "Abstract 3039: Identification of a novel biomarker of resistance to lapatinib common to both breast and oesophagogastric cancer" @default.
- W2036694029 doi "https://doi.org/10.1158/1538-7445.am2011-3039" @default.
- W2036694029 hasPublicationYear "2011" @default.
- W2036694029 type Work @default.
- W2036694029 sameAs 2036694029 @default.
- W2036694029 citedByCount "0" @default.
- W2036694029 crossrefType "proceedings-article" @default.
- W2036694029 hasAuthorship W2036694029A5015623213 @default.
- W2036694029 hasAuthorship W2036694029A5024558533 @default.
- W2036694029 hasAuthorship W2036694029A5044049673 @default.
- W2036694029 hasAuthorship W2036694029A5057324933 @default.
- W2036694029 hasAuthorship W2036694029A5058973407 @default.
- W2036694029 hasAuthorship W2036694029A5068311092 @default.
- W2036694029 hasAuthorship W2036694029A5069662009 @default.
- W2036694029 hasAuthorship W2036694029A5072699629 @default.
- W2036694029 hasAuthorship W2036694029A5077235697 @default.
- W2036694029 hasAuthorship W2036694029A5087812629 @default.
- W2036694029 hasConcept C121608353 @default.
- W2036694029 hasConcept C126322002 @default.
- W2036694029 hasConcept C143998085 @default.
- W2036694029 hasConcept C2775930923 @default.
- W2036694029 hasConcept C2776694085 @default.
- W2036694029 hasConcept C2777329042 @default.
- W2036694029 hasConcept C2779786085 @default.
- W2036694029 hasConcept C2781197716 @default.
- W2036694029 hasConcept C502942594 @default.
- W2036694029 hasConcept C530470458 @default.
- W2036694029 hasConcept C55493867 @default.
- W2036694029 hasConcept C71924100 @default.
- W2036694029 hasConcept C86803240 @default.
- W2036694029 hasConceptScore W2036694029C121608353 @default.
- W2036694029 hasConceptScore W2036694029C126322002 @default.
- W2036694029 hasConceptScore W2036694029C143998085 @default.
- W2036694029 hasConceptScore W2036694029C2775930923 @default.
- W2036694029 hasConceptScore W2036694029C2776694085 @default.
- W2036694029 hasConceptScore W2036694029C2777329042 @default.
- W2036694029 hasConceptScore W2036694029C2779786085 @default.
- W2036694029 hasConceptScore W2036694029C2781197716 @default.
- W2036694029 hasConceptScore W2036694029C502942594 @default.
- W2036694029 hasConceptScore W2036694029C530470458 @default.
- W2036694029 hasConceptScore W2036694029C55493867 @default.
- W2036694029 hasConceptScore W2036694029C71924100 @default.
- W2036694029 hasConceptScore W2036694029C86803240 @default.
- W2036694029 hasLocation W20366940291 @default.
- W2036694029 hasOpenAccess W2036694029 @default.
- W2036694029 hasPrimaryLocation W20366940291 @default.
- W2036694029 hasRelatedWork W1529301723 @default.
- W2036694029 hasRelatedWork W1976839295 @default.
- W2036694029 hasRelatedWork W1995407080 @default.
- W2036694029 hasRelatedWork W2037750068 @default.
- W2036694029 hasRelatedWork W2067018305 @default.
- W2036694029 hasRelatedWork W2095017507 @default.
- W2036694029 hasRelatedWork W2109529198 @default.
- W2036694029 hasRelatedWork W2249435371 @default.
- W2036694029 hasRelatedWork W2338921307 @default.
- W2036694029 hasRelatedWork W2411168480 @default.
- W2036694029 hasRelatedWork W2557666675 @default.
- W2036694029 hasRelatedWork W2563504190 @default.
- W2036694029 hasRelatedWork W2590543950 @default.
- W2036694029 hasRelatedWork W2591971327 @default.
- W2036694029 hasRelatedWork W2887003524 @default.
- W2036694029 hasRelatedWork W2895955393 @default.
- W2036694029 hasRelatedWork W2943938066 @default.
- W2036694029 hasRelatedWork W2955270445 @default.
- W2036694029 hasRelatedWork W2966425610 @default.
- W2036694029 hasRelatedWork W3166070177 @default.
- W2036694029 isParatext "false" @default.
- W2036694029 isRetracted "false" @default.
- W2036694029 magId "2036694029" @default.
- W2036694029 workType "article" @default.